Oric Pharmaceuticals
Denisse Carvajal Maldonado PhD is an accomplished scientist with extensive experience in molecular biology techniques and biochemistry. Currently serving as a Scientist at ORIC Pharmaceuticals Inc. since April 2023, Denisse has held previous positions including Postdoctoral Research Fellow at MD Anderson Cancer Center and Researcher at Saint Louis University. With a solid foundation in assay development established during tenure at Cytovance Biologics and academic experience as a Biochemistry Teaching Instructor at The University of Tulsa, Denisse is proficient in various laboratory techniques such as flow cytometry, RT-PCR, and DNA fiber analysis. Denisse earned a PhD in Biochemistry and Molecular Biology from Saint Louis University and holds both an MSc and BSc in Biochemistry from The University of Tulsa.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.